Vaccine to Target Brachyury for Oncology is under clinical development by Bavarian Nordic and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vaccine to Target Brachyury for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vaccine to Target Brachyury for Oncology overview
MVA-BN brachyury is under development for the treatment of solid tumors including non-small cell lung cancer, small cell lung cancer, metastatic chordoma, metastatic breast cancer, metastatic ovarian cancer, ER-/PR-/HER2+ breast cancer, metastatic colorectal cancer, triple-negative breast cancer, metastatic castrate-resistant prostate cancer, metastatic pancreatic cancer, bile duct cancer (Cholangiocarcinoma), metastatic hepatocellular cancer, Merkel cell carcinoma, metastatic bladder cancer, metastatic kidney cancer and lung cancer. It is administered through intravenous, subcutaneous and intratumor route. The therapeutic candidate consists of a primer (MVA-BN) and a booster dose (fowlpox), which have been modified to express brachyury and to encode three costimulatory molecules, known as TRICOM. It is developed based on MVA-BN, a recombinant poxvirus vector-vaccine platform technology, and TRICOM technology.
Bavarian Nordic overview
Bavarian Nordic is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara –Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, COVID-19, respiratory syncytial virus, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.
For a complete picture of Vaccine to Target Brachyury for Oncology’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
